Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco

Cost Effectiveness and Resource Allocation

Volumn 8, Issue , 2010, Pages

  Boutayeb, Saber ^a   Boutayeb, Abdesslam ^b,c   Ahbeddou, Naoual ^a   Boutayeb, Wiam ^b   Ismail, Essaadi ^a   Tazi, Mehdi ^a   Errihani, Hassan ^a  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b FACULTÉ DES SCIENCES   (Morocco)

^c Unité Associée au CNRST URAC04   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIMITOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; EARLY CANCER; HEALTH CARE COST; HUMAN; MOROCCO;

EID: 77956478978     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-8-16     Document Type: Article

References (11)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncology 2001, 2:133-40. 10.1016/S1470-2045(00)00254-0, 11902563.
2. Registry of tumour in Great Casablanca region: Annual Report. Casablanca 2004,
3. López-Tarruella S, Martín M. Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Research 2009, 11:204. 10.1186/bcr2226, 2688937, 19344489.
4. Gligorov J, Beuzeboc P. From San Antonio to Saint-Gallen: reflections of Saint-Paul-de-Vence or how to treat breast cancer. Bulletin of Cancer 2003, 90:278-83.
5. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006, 11:4-12. 10.1634/theoncologist.11-90001-4, 16971734.
6. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Annals of Oncology 2007, 18:1493-9. 10.1093/annonc/mdm185, 17761705.
7. Kacemi H. Breast cancer at the National Oncology Institute in 2004. PhD thesis 2006, Mohamed V University, Radiation Oncology Department.
8. Fagnani F, Colin X, Arveux P, Coudert B, Misset JL. Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer. Bulletin of Cancer 2007, 94:711-20.
9. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost?. BMJ 2006, 25:1118-20.
10. Fleck L. The costs of caring: Who pays? Who profits? Who panders?. Hastings Cent Rep 2006, 36:13-7. 10.1353/hcr.2006.0040, 16776017.
11. International Agency for Research on Cancer GLOBOCAN 2008: Cancer incidence and mortality worldwide in 2008. International Agency for Research on Cancer., http://globocan.iarc.fr